Logo image of ARGX

ARGENX SE - ADR (ARGX) Stock Fundamental Analysis

NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD

573.26  -7.69 (-1.32%)

After market: 573.26 0 (0%)

Fundamental Rating

5

Taking everything into account, ARGX scores 5 out of 10 in our fundamental rating. ARGX was compared to 560 industry peers in the Biotechnology industry. The financial health of ARGX is average, but there are quite some concerns on its profitability. ARGX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ARGX had positive earnings in the past year.
ARGX had a negative operating cash flow in the past year.
ARGX had negative earnings in 4 of the past 5 years.
In the past 5 years ARGX always reported negative operating cash flow.
ARGX Yearly Net Income VS EBIT VS OCF VS FCFARGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

With an excellent Return On Assets value of 13.41%, ARGX belongs to the best of the industry, outperforming 95.71% of the companies in the same industry.
Looking at the Return On Equity, with a value of 15.13%, ARGX belongs to the top of the industry, outperforming 95.18% of the companies in the same industry.
Industry RankSector Rank
ROA 13.41%
ROE 15.13%
ROIC N/A
ROA(3y)-5.24%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.94%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX Yearly ROA, ROE, ROICARGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

ARGX has a Profit Margin of 37.99%. This is amongst the best in the industry. ARGX outperforms 98.21% of its industry peers.
With an excellent Gross Margin value of 89.63%, ARGX belongs to the best of the industry, outperforming 91.61% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 37.99%
GM 89.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX Yearly Profit, Operating, Gross MarginsARGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARGX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARGX has more shares outstanding
ARGX has a worse debt/assets ratio than last year.
ARGX Yearly Shares OutstandingARGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ARGX Yearly Total Debt VS Total AssetsARGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

ARGX has an Altman-Z score of 31.26. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
ARGX's Altman-Z score of 31.26 is amongst the best of the industry. ARGX outperforms 97.32% of its industry peers.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ARGX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. ARGX outperforms 43.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 31.26
ROIC/WACCN/A
WACC7.57%
ARGX Yearly LT Debt VS Equity VS FCFARGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

A Current Ratio of 7.29 indicates that ARGX has no problem at all paying its short term obligations.
ARGX's Current ratio of 7.29 is fine compared to the rest of the industry. ARGX outperforms 68.04% of its industry peers.
A Quick Ratio of 6.68 indicates that ARGX has no problem at all paying its short term obligations.
ARGX's Quick ratio of 6.68 is fine compared to the rest of the industry. ARGX outperforms 66.07% of its industry peers.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 6.68
ARGX Yearly Current Assets VS Current LiabilitesARGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 194.52% over the past year.
ARGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 78.63%.
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 94.61% on average per year.
EPS 1Y (TTM)194.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%348.08%
Revenue 1Y (TTM)78.63%
Revenue growth 3Y63.91%
Revenue growth 5Y94.61%
Sales Q2Q%95.72%

3.2 Future

The Earnings Per Share is expected to grow by 106.31% on average over the next years. This is a very strong growth
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 31.13% on average per year.
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue Next Year64.81%
Revenue Next 2Y47.5%
Revenue Next 3Y39.17%
Revenue Next 5Y31.13%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX Yearly Revenue VS EstimatesARGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ARGX Yearly EPS VS EstimatesARGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60 80

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 97.66, the valuation of ARGX can be described as expensive.
Based on the Price/Earnings ratio, ARGX is valued cheaper than 91.43% of the companies in the same industry.
When comparing the Price/Earnings ratio of ARGX to the average of the S&P500 Index (26.25), we can say ARGX is valued expensively.
With a Price/Forward Earnings ratio of 25.71, ARGX can be considered very expensive at the moment.
ARGX's Price/Forward Earnings ratio is rather cheap when compared to the industry. ARGX is cheaper than 90.89% of the companies in the same industry.
ARGX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.15.
Industry RankSector Rank
PE 97.66
Fwd PE 25.71
ARGX Price Earnings VS Forward Price EarningsARGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARGX Per share dataARGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 155.24% in the coming years.
PEG (NY)0.17
PEG (5Y)N/A
EPS Next 2Y242.7%
EPS Next 3Y155.24%

More info and screens

0

5. Dividend

5.1 Amount

ARGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARGENX SE - ADR

NASDAQ:ARGX (5/30/2025, 8:00:00 PM)

After market: 573.26 0 (0%)

573.26

-7.69 (-1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners39.35%
Inst Owner Change-2.53%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap35.00B
Analysts84.62
Price Target792.74 (38.29%)
Short Float %3.75%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7909.56%
Min EPS beat(2)-38.07%
Max EPS beat(2)15857.2%
EPS beat(4)2
Avg EPS beat(4)3984.41%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)2003.12%
EPS beat(12)8
Avg EPS beat(12)1344.81%
EPS beat(16)12
Avg EPS beat(16)1027.8%
Revenue beat(2)2
Avg Revenue beat(2)6.37%
Min Revenue beat(2)5.75%
Max Revenue beat(2)6.99%
Revenue beat(4)3
Avg Revenue beat(4)5.41%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)9.17%
Revenue beat(8)7
Avg Revenue beat(8)8.22%
Revenue beat(12)11
Avg Revenue beat(12)28.07%
Revenue beat(16)14
Avg Revenue beat(16)44.01%
PT rev (1m)2.67%
PT rev (3m)18.3%
EPS NQ rev (1m)2.35%
EPS NQ rev (3m)31.14%
EPS NY rev (1m)0%
EPS NY rev (3m)11.78%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)8.12%
Revenue NY rev (1m)0.41%
Revenue NY rev (3m)5.09%
Valuation
Industry RankSector Rank
PE 97.66
Fwd PE 25.71
P/S 15.98
P/FCF N/A
P/OCF N/A
P/B 6.37
P/tB 6.58
EV/EBITDA N/A
EPS(TTM)5.87
EY1.02%
EPS(NY)22.3
Fwd EY3.89%
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS35.87
BVpS90.06
TBVpS87.1
PEG (NY)0.17
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.41%
ROE 15.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 37.99%
GM 89.63%
FCFM N/A
ROA(3y)-5.24%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 937.93%
Cap/Sales 3.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 6.68
Altman-Z 31.26
F-Score2
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)606.32%
Cap/Depr(5y)803.99%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)194.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%348.08%
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue 1Y (TTM)78.63%
Revenue growth 3Y63.91%
Revenue growth 5Y94.61%
Sales Q2Q%95.72%
Revenue Next Year64.81%
Revenue Next 2Y47.5%
Revenue Next 3Y39.17%
Revenue Next 5Y31.13%
EBIT growth 1Y96.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1034.03%
EBIT Next 3Y192.38%
EBIT Next 5Y115.14%
FCF growth 1Y67.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.24%
OCF growth 3YN/A
OCF growth 5YN/A